Does it excite you to work with translational pharmacology? and do you have experience within obesity pharmacology? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position
As a scientist within Translational Pharmacology, you will support both our research projects and development projects with high quality and efficient in-house and CRO in vivo/ex vivo pharmacology studies. In that connection you will conduct MoA studies to generate the scientific story for our drug targets and explore how our drug candidates differentiate compared to marketed drugs.
We offer exciting responsibilities:
Act as Study Director for both in-house and CRO studies. This includes designing, conduction, interpretation, and reporting of in vivo/ex vivo pharmacology studies.
Develop needed pharmacology models to ensure our project progress.
Support the projects with in-depth disease and biology understanding.
Identify new potential drug targets and suggest new early research projects.
Your profile
You have a genuine interest in obesity, with a particular focus on obesity-related neuroscience, biomarker discovery, and translational research. As a person, you are an excellent communicator, demonstrated through the ability to build and maintain productive relationships across functions and levels. Additionally, you are good at taking ownership and proactively managing your tasks and projects.
Key competencies:
Preferable minimum 2 years postdoc experience
FELASA certificate
Experience in developing and running animal models within obesity. Experience within obesity related neuroscience including models within this research area is a significant advantage
Proficient in statistical analysis
Experience in interpretation, reporting and publication of study results
If you have experience with some of the below, it is only an advantage:
Experience with muscle, adipose and/or liver tissue biology including models evaluating this
Experience with indirect calorimetry and feeding systems
Experience with ex vivo techniques (e.g. primary cells, organoids, FACS and biomarker analysis and identification).
Your new team
Translational Pharmacology is a part of Zealand Pharma’s Discovery Research organization which identifies new drug targets and drives them forward to clinical trials. In close collaboration with other functions within Discovery Research we support the delivery of high-quality drug candidates within a short time frame to our Clinical development organization.
The Translational Pharmacology function consists of 3 in vivo departments, counting 29 people in total.
Let’s bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold
Interested in bonding with us? Then please apply no later than November 20, 2025, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
For further information, please contact Head of Translational Pharmacology, Senior Director, Erik Max Wulff, [email protected]
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Top Skills
What We Do
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases.
Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn
